Literature DB >> 30824957

Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma.

Ryo Nakagawa1, Yasushi Onishi2, Akihisa Kawajiri1, Koichi Onodera1, Eijiro Furukawa1, Sayaka Sano1, Kei Saito1, Satoshi Ichikawa1, Tohru Fujiwara1, Noriko Fukuhara1, Hideo Harigae1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30824957     DOI： 10.1007/s00277-019-03645-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  4 in total

1.  Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy.

Authors:  Takaki Kikuchi; Shigeru Kusumoto; Yasuhito Tanaka; Yoshiko Oshima; Haruna Fujinami; Tomotaka Suzuki; Haruhito Totani; Shiori Kinoshita; Yu Asao; Tomoko Narita; Asahi Ito; Masaki Ri; Hirokazu Komatsu; Shinsuke Iida
Journal:  J Clin Exp Hematop       Date:  2020-05-13

Review 2.  Toxicity management strategies for next-generation novel therapeutics in multiple myeloma.

Authors:  Mary Steinbach; Kelley Julian; Brian McClune; Douglas W Sborov
Journal:  Ther Adv Hematol       Date:  2022-07-15

Review 3.  Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? - Literature review.

Authors:  Luana Mota Ferreira; Jaderson Lima Cerezer; Mailine Gehrcke
Journal:  Hematol Transfus Cell Ther       Date:  2020-07-22

Review 4.  Roles of CD38 in the Immune Response to Infection.

Authors:  Estibaliz Glaría; Annabel F Valledor
Journal:  Cells       Date:  2020-01-16       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.